Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
about
Cheiradone: a vascular endothelial cell growth factor receptor antagonist.Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.Targeted antiangiogenesis gene therapy using targeted cationic microbubbles conjugated with CD105 antibody compared with untargeted cationic and neutral microbubblesImpact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer.Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure.Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapyA novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activityAECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton.Metastasis: recent discoveries and novel treatment strategies.Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathwaysBeyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiationRole of bevacizumab in colorectal cancer growth and its adverse effects: a review.Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma.Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.Using monoclonal antibodies to stimulate antitumor cellular immunity.Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.Targeting angiogenesis for treatment of human cancerBevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.Therapeutic application of anti-angiogenic nanomaterials in cancers.Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.Placental growth factor: What hematologists need to know.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesis.Short term apoptotic activity of intravitreal bevacizumab on rabbit retina.Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.Engineering therapeutic monoclonal antibodies.Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients.Bloch surface wave enhanced biosensor for the direct detection of Angiopoietin-2 tumor biomarker in human plasma.
P2860
Q33317046-A85E8A4A-CDBD-43DA-A37B-82FBC81901B2Q33625077-5E956D1D-A6E4-4B87-8507-6F712C61F884Q34972161-0D50A21A-D377-4BDA-9406-0F539A09E85EQ35086518-52E368BD-410D-4722-8DEE-37323A6282C5Q35136797-79CDD666-B88D-4BEF-84F6-F8A405482B88Q35161745-3687D9B7-63B4-4B5C-8289-87B30EBAB8D4Q35213093-C9A9A109-8DB4-454D-8219-AB2D3300F888Q35243299-BC97B9C8-FF9C-4A4A-B1A1-A217EC096A49Q35284618-1C5A26DB-6CE6-4DEF-B724-115399554579Q35604265-0C80EEAA-8355-4C0C-A7D7-46B913947141Q35757079-403DADEF-7610-4B23-819B-4DF22206C3EFQ36407511-E410E535-4053-4498-8C7B-A53610E1D1ECQ36545995-9A867BF3-D108-4048-B44F-6136D7667A63Q36881812-FBCB8108-5CD2-4D2C-9187-071638BA6CF5Q36891571-86E84FF8-340A-42A5-972D-8C2E559C51D7Q37102447-B1B8A9B9-AF0A-4BC4-A983-5DDBE33CAD3DQ37655483-6211F479-20B2-46A7-BE96-41594797A3DEQ37707034-332B6AD3-9B39-4629-9338-7FD379DDC78CQ37721914-DC2E82E8-C4DD-4718-B80B-27FFD1277FB0Q37909430-AB8DACCE-07BB-4B9A-992C-934A1741C6FFQ37997307-D3970A1A-C092-4692-917E-14BC71B1F588Q38125442-309A3470-3C3B-4E5F-947F-F69630A302B6Q38690276-023C0F2E-6096-4666-AF74-670618C4C1F0Q38805034-E55C8D2A-B21D-48F7-B896-29D533CF4CF1Q38816319-9108AC38-F50A-424D-9B12-6468C1ADF166Q38823169-2A932D2D-F770-43E7-8E2B-291A1A22E363Q39110385-B6CED269-1213-4542-A3C1-E28BA68E3036Q39432031-8990B8E9-B1D0-46C1-9531-DD00D61DB81CQ39663158-5A239C70-9C40-4FB4-9E1B-A969669E236BQ42772642-2883B682-2BC5-4435-9953-97B52CACE4E4Q47114557-7B99F86D-2080-43F8-A5F2-5CBBC00D94C4Q47165594-ED129B9C-50E7-4F7A-9F29-C0671CF924D8Q47820029-E86FD396-D325-421C-AEB1-FA93FF343638Q48226662-124E3942-AB98-4770-BE57-DD1255DBCD61Q50181358-B0A17712-2E1D-468F-9234-C0D9C77BF9D1Q52649539-4E447077-AA13-4EE3-8A96-69F3744C7C0E
P2860
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@ast
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@en
type
label
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@ast
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@en
prefLabel
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@ast
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@en
P921
P1476
Bevacizumab, a humanized anti- ...... reatment of colorectal cancer.
@en
P2093
P356
10.1111/J.1365-2710.2007.00800.X
P577
2007-02-01T00:00:00Z